Journal ArticleDOI
Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Ian C. Lawrance,Graham L. Radford-Smith,Graham L. Radford-Smith,Peter A. Bampton,Jane M. Andrews,Pok-Kern Tan,Anthony Croft,Richard B. Gearry,Timothy H. Florin +8 more
Reads0
Chats0
TLDR
The aim of this study was to examine the Australian/New Zealand experience of serious infections and TB in IBD patients receiving anti‐TNF‐α therapy from 1999–2009.Abstract:
Ian C Lawrance, Graham L Radford-Smith, Peter A Bampton, Jane M Andrews, Pok-Kern Tan, Anthony Croft, Richard B Gearry and Timothy H J Florinread more
Citations
More filters
Journal ArticleDOI
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.
TL;DR: Factors such as severe IBD, elevated levels of fecal calprotectin, and the use of immunosuppressive medications, especially when used in combination, are major risk factors for opportunistic infections in IBD patients.
Journal ArticleDOI
What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?
TL;DR: This review aims to provide other options for the physician, to remind them of the olderestablished medications like azathioprine/6-mercaptopurine and methotrexate, the less established medications like mycophenolate mofetil and tacrolimus as well as newer therapeutic options like the anti-integins, which block the trafficking of leukocytes into the intestinal mucosa.
Journal ArticleDOI
S2k‐Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen – Kurzfassung Teil 2
Lisa Eisert,Matthias Augustin,Sabine Bach,Martin Dittmann,Renate Eiler,Regina Fölster-Holst,Sascha Gerdes,Henning Hamm,Peter Höger,Gerd Horneff,Ralph von Kiedrowski,Sandra Philipp,Marc Pleimes,Martin Schlaeger,Volker Schuster,Petra Staubach,Tobias Weberschock,Ricardo Niklas Werner,Alexander Nast,Michael Sticherling +19 more
TL;DR: Diese Leitlinie richtet sich an Assistenz‐ und Fachärzte der Dermatologie, Pädiatrie, Kinderdermatologies and Kinderrheumatologie sowie an Kostenträger and politische Entscheidungsgremien.
Journal ArticleDOI
Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs.
Sergio Fernandez-Martinez,Xavier Cortes,Joaquín Borrás-Blasco,Antonio Gracia-Pérez,Elvira Casterá +4 more
TL;DR: This vaccination program decreases infectious complications and was associated with a lower amount of hospital admissions due to infections, emergency room visits and the rate of invasive pneumococcal disease.
Journal Article
Mucormycosis of the intestine: a rare complication in Crohn's disease.
TL;DR: This report presents a rare case of gastrointestinal mucormycosis following treatment with corticosteroids in the setting of inflammatory bowel disease.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frederic Colombel,William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Remo Panaccione,Stefan Schreiber,Dan Byczkowski,Ju Li,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Related Papers (5)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier,Fernando Magro,Candida Abreu,Alessandro Armuzzi,Shomron Ben-Horin,Yehuda Chowers,Mario Cottone,L. de Ridder,Glen A. Doherty,Robert Ehehalt,Maria Esteve,K.H. Katsanos,Charlie W. Lees,Eithne MacMahon,Tom G. Moreels,Walter Reinisch,Herbert Tilg,Lydjie Tremblay,Gigi Veereman-Wauters,N. Viget,Yazdan Yazdanpanah,Rami Eliakim,Jean-Frederic Colombel +22 more